Prognostic Role of Hypoxia-Inducible Factor-2? Tumor Cell Expression in Cancer Patients: A Meta-Analysis.
Ontology highlight
ABSTRACT: Hypoxia-inducible factor-2? (HIF-2?) plays an important role in tumor progression and metastasis. A number of studies have evaluated the correlation between HIF-2? overexpression and clinical outcome in cancer patients but yielded inconsistent results. To comprehensively and quantitatively summarize the evidence on the capability of HIF-2? to predict the prognosis of cancer patients with solid tumors, a meta-analysis was carried out. Renal cell carcinoma (CC-RCC) was separately analyzed due to an alternative mechanism of regulation. Systematic literature searches were performed in PubMed and Embase databases for relevant original articles until February 2018. Forty-nine studies with 6,052 patients were included in this study. The pooled hazard ratios (HRs) with corresponding confidence intervals were calculated to assess the prognostic value of HIF-2? protein expression in tumor cells. The meta-analysis revealed strong significant negative associations between HIF-2? expression and five endpoints: overall survival [HR?=?1.69, 95% confidence interval (95% CI) 1.39-2.06], disease-free survival (HR?=?1.87, 95% CI 1.2-2.92), disease-specific survival (HR?=?1.57, 95% CI 1.06-2.34), metastasis-free survival (HR?=?2.67, 95% CI 1.32-5.38), and progression-free survival (HR?=?2.18, 95% CI 1.25-3.78). Subgroup analyses revealed similar associations in the majority of tumor sites. Overall, these data demonstrate a negative prognostic role of HIF-2? in patients suffering from different types of solid tumors.
SUBMITTER: Moreno Roig E
PROVIDER: S-EPMC6004384 | biostudies-literature | 2018
REPOSITORIES: biostudies-literature
ACCESS DATA